Document is current
Any future updates will be listed below
-
Authors
Yang, Hong https://orcid.org/0009-0002-0414-2471
Zhang, Cheng https://orcid.org/0000-0002-3721-8586
Turkez, Hasan
Uhlen, Mathias https://orcid.org/0000-0002-4858-8056
Boren, Jan https://orcid.org/0000-0003-0786-8091
Mardinoglu, Adil https://orcid.org/0000-0002-4254-6090
- License Information
-
More Information
Article History
Received: 18 July 2022
Accepted: 28 March 2023
First Online: 11 May 2023
Competing interests
: A.M., J.B. and M.U. are the founders and shareholders of ScandiBio Therapeutics, and they filed a patent application (US11141396B2) on the use of combined metabolic activators including serine to treat NAFLD patients. The other authors declare no competing interests.
